Table 1.
GAG sample | Mwa (kDa) | ndsb | PDI (Mw/Mn) | Linker from GAG to biotinf | Provider/reference |
---|---|---|---|---|---|
HAdp4-b | 0.8 | 2 | 1.0e | = N–O–CH2–CO–NH–(CH2)2–EG3–CH–NH–CO–(CH2)4– | 52 |
HAdp10-b | 2.0 | 5 | 1.0e | = N–O–CH2–CO–NH–(CH2)2–EG3–CH–NH–CO–(CH2)4– | 52 |
HAdp15-b | 3.0 | 7.5 | 1.0e | –O–(CH2)3–S–(CH2)2–NH–CO–(CH2)4– | 52,53 |
HA10-b | 13 ± 1 | 32.5 ± 2c | –NH–CO–(CH2)5–NH–CO–(CH2)4– | 47 | |
HA30-b | 38 ± 2 | 95 ± 5c | –NH–CO–(CH2)5–NH–CO–(CH2)4– | 47 | |
HA50-b | 58 ± 3 | 145 ± 8c | 1.007d | –NH–CO–(CH2)5–NH–CO–(CH2)4– | Hyalose47 |
HA100-b | 100 ± 5 | 250 ± 13 | 1.011d | –NH–CO–(CH2)5–NH–CO–(CH2)4– | 47 |
HA300-b | 317 ± 16 | 793 ± 40c | 1.03d | –NH–CO–(CH2)5–NH–CO–(CH2)4– | 47 |
HA500-b | 520 ± 26 | 1300 ± 65c | –NH–CO–(CH2)5–NH–CO–(CH2)4– | Hyalose47 | |
HA1000-b | 838 ± 42 | 2095 ± 105c | 1.003d | –NH–CO–(CH2)5–NH–CO–(CH2)4– | Hyalose47 |
HA250 | 273 ± 14 | 683 ± 35c | – | Hyalose47 | |
C0-b | 276 ± 14 | 690 ± 35c | 1.006d | –NH–CO–(CH2)5–NH–CO–(CH2)4– | 49,50 |
Hep-b | 95 ± 5 | 238 ± 12c | 1.013d | –NH–CO–(CH2)5–NH–CO–(CH2)4– | 48 |
Hep-b | 307 ± 16 | 768 ± 39c | 1.012d | –NH–CO–(CH2)5–NH–CO–(CH2)4– | 48 |
HSdp6-b | 3 | 1.0e | = N–O–CH2–CO–NH–(CH2)2–EG3–CH–NH–CO–(CH2)4– | 52 | |
HSdp8-b | 4 | 1.0e | = N–O–CH2–CO–NH–(CH2)2–EG3–CH–NH–CO–(CH2)4– | 52 | |
HSdp10-b | 5 | 1.0e | = N–O–CH2–CO–NH–(CH2)2–EG3–CH–NH–CO–(CH2)4– | 52 | |
HSdp12-b | 6 | 1.0e | = N–O–CH2–CO–NH–(CH2)2–EG3–CH–NH–CO–(CH2)4– | 52 |
aMw as per manufacturer’s specifications (excluding the mass of the biotin and linker). Based on the polydispersity index (PDI) for most polysaccharides, errors for all size-defined GAG polysaccharides were conservatively estimated to ± 5%.
bNumber of disaccharides per chain, nds.
cCalculated from MW and a molecular mass of 400 Da per disaccharide.
dPDI for polysaccharides determined by SEC–MALLS, as per manufacturer’s specification.
eOligosaccharides were purified by size, and are assumed to have a PDI close to 1.
fBiotin was conjugated to C1 of N-acetylglucosamine (for HA-b and HS-b) and N-acetylgalactosamine (for C0-b) at the reducing end of the GAGs; EG ethylene glycol.